Literature DB >> 7794931

Peptide aldehyde inhibitors of hepatitis A virus 3C proteinase.

B A Malcolm1, C Lowe, S Shechosky, R T McKay, C C Yang, V J Shah, R J Simon, J C Vederas, D V Santi.   

Abstract

Picornaviral 3C proteinases are a group of closely related thiol proteinases responsible for processing of the viral polyprotein into its component proteins. These proteinases adopt a chymotrypsin-like fold [Allaire et al. (1994) Nature 369, 72-77; Matthews et al. (1994) Cell 77, 761-771] and a display an active-site configuration like those of the serine proteinases. Peptide-aldehydes based on the preferred peptide substrates for hepatitis A virus (HAV) 3C proteinase were synthesized by reduction of a thioester precursor. Acetyl-Leu-Ala-Ala-(N,N'-dimethylglutaminal) was found to be a reversible, slow-binding inhibitor for HAV 3C with a Ki* of (4.2 +/- 0.8) x 10(-8) M. This inhibitor showed 50-fold less activity against the highly homologous human rhinovirus (strain 14) 3C proteinase, whose peptide substrate specificity is slightly different, suggesting a high degree of selectivity. NMR spectrometry of the adduct of the 13C-labeled inhibitor with the HAV-3C proteinase indicate that a thiohemiacetal is formed between the enzyme and the aldehyde carbon as previously noted for peptide-aldehyde inhibitors of papain [Lewis & Wolfenden (1977) Biochemistry 16,4890-4894; Gamcsik et al. (1983) J. Am. Chem. Soc. 105, 6324-6325]. The adduct can also be observed by electrospray mass spectrometry.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7794931     DOI: 10.1021/bi00025a024

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  17 in total

1.  Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.

Authors:  D A Matthews; P S Dragovich; S E Webber; S A Fuhrman; A K Patick; L S Zalman; T F Hendrickson; R A Love; T J Prins; J T Marakovits; R Zhou; J Tikhe; C E Ford; J W Meador; R A Ferre; E L Brown; S L Binford; M A Brothers; D M DeLisle; S T Worland
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity.

Authors:  Aaron M LeBeau; Pratap Singh; John T Isaacs; Samuel R Denmeade
Journal:  Biochemistry       Date:  2009-04-21       Impact factor: 3.162

3.  Benzyloxycarbonylprolylprolinal, a transition-state analogue for prolyl oligopeptidase, forms a tetrahedral adduct with catalytic serine, not a reactive cysteine.

Authors:  A Kahyaoglu; K Haghjoo; F Kraicsovits; F Jordan; L Polgar
Journal:  Biochem J       Date:  1997-03-15       Impact factor: 3.857

4.  Human pDCs preferentially sense enveloped hepatitis A virions.

Authors:  Zongdi Feng; You Li; Kevin L McKnight; Lucinda Hensley; Robert E Lanford; Christopher M Walker; Stanley M Lemon
Journal:  J Clin Invest       Date:  2014-11-21       Impact factor: 14.808

5.  Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.

Authors:  Robert L Hoffman; Robert S Kania; Mary A Brothers; Jay F Davies; Rose A Ferre; Ketan S Gajiwala; Mingying He; Robert J Hogan; Kirk Kozminski; Lilian Y Li; Jonathan W Lockner; Jihong Lou; Michelle T Marra; Lennert J Mitchell; Brion W Murray; James A Nieman; Stephen Noell; Simon P Planken; Thomas Rowe; Kevin Ryan; George J Smith; James E Solowiej; Claire M Steppan; Barbara Taggart
Journal:  J Med Chem       Date:  2020-10-15       Impact factor: 7.446

Review 6.  Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus.

Authors:  Tatsuo Kanda; Shingo Nakamoto; Shuang Wu; Masato Nakamura; Xia Jiang; Yuki Haga; Reina Sasaki; Osamu Yokosuka
Journal:  J Clin Transl Hepatol       Date:  2015-09-15

7.  Solid-phase synthesis and screening of a library of C-terminal arginine peptide aldehydes against Murray Valley encephalitis virus protease.

Authors:  Nicholas J Ede; Jeffrey Hill; Joma K Joy; Anne-Marie Ede; Merran L Koppens
Journal:  J Pept Sci       Date:  2012-09-18       Impact factor: 1.905

Review 8.  Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies.

Authors:  Wayne Vuong; Conrad Fischer; Muhammad Bashir Khan; Marco J van Belkum; Tess Lamer; Kurtis D Willoughby; Jimmy Lu; Elena Arutyunova; Michael A Joyce; Holly A Saffran; Justin A Shields; Howard S Young; James A Nieman; D Lorne Tyrrell; M Joanne Lemieux; John C Vederas
Journal:  Eur J Med Chem       Date:  2021-05-30       Impact factor: 7.088

9.  Suppression of La antigen exerts potential antiviral effects against hepatitis A virus.

Authors:  Xia Jiang; Tatsuo Kanda; Shuang Wu; Shingo Nakamoto; Kengo Saito; Hiroshi Shirasawa; Tomoko Kiyohara; Koji Ishii; Takaji Wakita; Hiroaki Okamoto; Osamu Yokosuka
Journal:  PLoS One       Date:  2014-07-07       Impact factor: 3.240

10.  Viral cysteine proteinases.

Authors:  Alexander E Gorbalenya; Eric J Snijder
Journal:  Perspect Drug Discov Des       Date:  1996
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.